
Christian Angermayer became a multimillionaire before turning 25 thanks to the merger of Alnylam with Ribopharma. We talk about his diverse investment appetite and the rise of consumer biotech and human enhancement.We talk about GLP-1s, the progress of AtaiBeckley, and why he thinks ‘going home and sleeping’ beats an all-nighter every time.---Discover the best biotech companies in 🇪🇺 with the FlotBio Map at https://bit.ly/4nXmKjN---⭐️ ABOUT THE SPEAKERChristian is the founder of Apeiron Investment Group, which manages around $7 billion across psychedelics, longevity, consumer biotech, crypto and media. He also co-founded big companies including AtaiBeckley and the Enhanced Games.Christian studied business in Germany at the University of Bayreuth but dropped out to co-found Ribopharma, which merged with Alnylam Pharmaceuticals in 2003.🔗 LINKS MENTIONEDChristian Angermayer LinkedIn profile — https://www.linkedin.com/in/christian-angermayer/Enhanced Games — https://www.enhanced.com/Enhanced Games inaugural event press release — https://investors.enhanced.com/inaugural-enhanced-games-deliver-a-world-record-and-21-personal-bests-showcasing-that-living-enhanced-works/David Nutt LinkedIn profile — https://www.linkedin.com/in/professor-david-nutt-82498025/AtaiBeckley pipeline — https://www.ataibeckley.com/our-work/pipelineBBC weight loss drugs comparison — https://www.bbc.com/news/articles/c981044pgvyoDavid Nutt drug-harm chart — https://commons.wikimedia.org/wiki/File:HarmCausedByDrugsTable.svgMatthew Walker, *Why We Sleep* — https://www.amazon.com/Why-We-Sleep-Unlocking-Dreams/dp/1501144316Mayo Clinic report on resveratrol/red wine — https://www.mayoclinic.org/diseases-conditions/heart-disease/in-depth/red-wine/art-20048281CNBC — atai's 2021 Wall Street debut — https://www.cnbc.com/2021/06/18/peter-thiel-backed-psychedelic-start-ups-shares-pop-in-wall-street-debut.htmlFortune article on Angermayer's uranium bet — https://fortune.com/crypto/2025/05/27/christian-angermayer-uranium-digital-german-billionaire-tether/Robert Nelsen, ARCH Venture Partners — https://www.archventure.com/team/robert-nelsen/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/christian-angermayer-glp-1s/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVI
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

ImCheck ex-CEO on ASCO Oncology Trends, $1.2B Exit and French Biotech | Pierre d’Epenoux | E60

CEO Jean-François Brepson on Scaling a CRO, and Selling to Charles River | E59 [Sponsored]

Ex-CEO of Incyte Hervé Hoppenot on 10x Growth, Biotech Cycles, and Breaking Bureaucracy | E58

Christoph Lengauer, Curie.Bio | Biotech Founders, Venture Capital | E57
Free AI-powered recaps of Flot.bio x Philip Hemme and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.